SWEDISH ORPHAN BIOVITRUM
🇫🇷France
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2009-03-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Registration Number
- NCT00540332
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 27
- Registration Number
- NCT00460421
- Locations
- 🇺🇸
University of Texas, Dallas, Texas, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Loma Linda University, Loma Linda, California, United States
Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 193
- Registration Number
- NCT00452777
- Locations
- 🇿🇦
Biovitrum Investigational Site, Wynberg, South Africa
🇨🇿Biovitrum investigational site, Praha 8, Czech Republic
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 281
- Registration Number
- NCT00434161
- Locations
- 🇩🇪
Universitatsklinikum Leipzig, Leipzig, Germany
Palifermin DDI (Drug Drug Interaction)
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 45
- Registration Number
- NCT00361348
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 145
- Registration Number
- NCT00352703
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 155
- Registration Number
- NCT00189488
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 47
- Registration Number
- NCT00109031
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 188
- Registration Number
- NCT00101582
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-10-27
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 100
- Registration Number
- NCT00094861
© Copyright 2024. All Rights Reserved by MedPath